Low-Protein Diet Slows Liver Cancer Growth: Rutgers Study Reveals Mechanism in Impaired Livers

🔬 Breakthrough from Rutgers Cancer Institute

A groundbreaking study led by researchers at Rutgers Cancer Institute of New Jersey has revealed that a simple dietary adjustment—reducing protein intake—could significantly slow the growth of liver cancer in individuals with compromised liver function. Published in Science Advances on January 9, 2026, the research titled "Impaired nitrogenous waste clearance promotes hepatocellular carcinoma" demonstrates how low-protein diets mitigate tumor progression in mouse models by addressing a key metabolic vulnerability: ammonia buildup.

Senior author Wei-Xing Zong, a distinguished professor at the Rutgers Ernest Mario School of Pharmacy, emphasized the potential impact: "If you have liver disease or damage that prevents your liver from functioning correctly, you should seriously consider reducing your protein intake to lower the risk of developing liver cancer." This finding opens new avenues for preventive nutrition strategies tailored to those at high risk for hepatocellular carcinoma (HCC), the most common form of liver cancer.

The study not only uncovers the causal role of impaired nitrogen waste clearance in driving HCC but also positions protein restriction as a feasible intervention. For millions affected by chronic liver conditions, this could mean a practical step toward reducing cancer risk without relying solely on pharmaceuticals.

Liver Cancer: Understanding the Scope and Risk Factors

Hepatocellular carcinoma accounts for about 75-85% of primary liver cancers and remains one of the deadliest malignancies worldwide. In the United States, the American Cancer Society projects approximately 42,240 new cases and 30,090 deaths in 2025, with a stark five-year survival rate of around 22%. Globally, cases are expected to rise from 870,000 in 2022 to over 1.5 million by later projections, driven by rising incidences of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), viral hepatitis, alcohol-related damage, and cirrhosis.

Cirrhosis, scarring of the liver from long-term injury, elevates HCC risk dramatically—up to 80 times higher than in healthy livers. About 1 in 4 U.S. adults grapples with fatty liver disease, a precursor that, combined with obesity and diabetes, fuels this epidemic. Early detection via ultrasound and alpha-fetoprotein testing is crucial, but prevention through lifestyle remains paramount.

Factors like chronic hepatitis B or C infection, excessive alcohol consumption, aflatoxin exposure, and non-alcoholic steatohepatitis (NASH) compound risks. In these impaired livers, routine processes falter, setting the stage for cancerous transformations as seen in the Rutgers investigation.

The Science Behind Ammonia and the Urea Cycle

Proteins from food are broken down into amino acids, releasing nitrogen that forms ammonia—a toxic byproduct harmful to the brain and body if accumulated. In a healthy liver, the urea cycle detoxifies this via enzymes like carbamoyl phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL), and arginase 1 (ARG1). These urea cycle enzymes (UCEs), concentrated in liver zones 1-2, convert ammonia into urea for urinary excretion. Glutamine synthetase (GS) mops up residuals in zone 3.

In diseased livers, UCE expression drops heterogeneously, impairing clearance and causing hyperammonemia. This has long been observed in HCC patients, correlating with poor prognosis, but causation was unclear until the Rutgers team proved ammonia overload reprograms metabolism. Excess ammonia diverts into amino acid synthesis and pyrimidine nucleotides—essential for DNA replication and tumor proliferation—while activating the mTORC1 pathway, spurring growth via phosphorylation of S6 and 4EBP1.

Spatial metabolomics confirmed higher ammonia in tumor interstitial fluid, with elevated precursors like dihydroorotate and orotate. This metabolic hijacking explains why chronic liver impairment primes the organ for cancer.

Details of the Rutgers Study: Methods and Striking Results

The Rutgers team employed sophisticated mouse models to dissect this process. They used hydrodynamic tail vein injection (HTVI) of oncogenes like c-MET/ΔN90-β-catenin, which rapidly represses UCEs, mimicking human HCC where β-catenin activation inversely correlates with enzyme levels. A contrasting c-MET/sgAxin1 model preserved UCEs for comparison.

Carcinogen models included diethylnitrosamine (DEN) with phenobarbital (PB) promotion or high-fat diet (HFD). Gene editing via sgRNA silenced individual UCEs (CPS1, ASS1, ASL, ARG1), accelerating tumor burden: liver-to-body weight ratios surged (P < 0.0001), proliferation markers (PCNA) rose, fibrosis increased (α-SMA), and survival plummeted per Kaplan-Meier analysis.

Metabolomics via LC-MS and ¹⁵N-ammonium chloride tracing showed ammonia fueling pyrimidines (e.g., N-carbamoyl-aspartate up), non-essential amino acids, and TCA cycle intermediates. Single-nucleus RNA-seq revealed pathway shifts in oncogene-expressing hepatocytes.

Critically, diets varied: standard chow (21.6% kcal protein), low-protein diet (LPD, 6.5% kcal), high-protein (42.6% kcal). LPD, initiated at weaning or pre-injection, slashed plasma/liver ammonia (P < 0.0001), tempered UCE repression, curbed mTORC1/fibrosis/proliferation, reduced tumor incidence (e.g., fewer nodules), and extended survival dramatically (log-rank P < 0.0001). Liver weights dropped significantly across DEN/PB and β-catenin models.

Photo by Aleksander Saks on Unsplash

• Tumor growth slowed by reducing nitrogen load.
• Pyrimidine metabolites normalized.
• Pathways shifted toward insulin/glucose responses, away from fatty acid catabolism.

Mechanism: How Protein Restriction Halts Cancer Progression

By limiting dietary protein, LPD curbs gut-derived ammonia influx, easing the burdened urea cycle. This prevents diversion to oncogenic pathways: less mTORC1 activation means restrained cell growth; normalized pyrimidines limit nucleotide pools for rapid division. Fibrosis markers wane, preserving liver architecture.

"The ammonia goes into amino acids and nucleotides, both of which tumor cells depend on for growth," Zong noted. LPD thus starves the tumor metabolically without broad calorie cuts, preserving energy for healthy cells. In contrast, high-protein exacerbated issues minimally, underscoring context-specificity for impaired livers.

Potential Benefits for At-Risk Individuals

For those with MASLD, NASH, cirrhosis, or post-hepatitis scarring—where 25% of U.S. adults fall—this suggests monitoring ammonia alongside AFP screening. Protein reduction could complement surveillance, potentially delaying HCC onset. Rutgers University press release highlights implications for fatty liver patients.

Early adopters might integrate via plant-based shifts, but personalization is key. Ongoing ammonia blood tests could guide adjustments, bridging preclinical promise to clinics.

Important Cautions and When to Consult a Professional

Healthy livers process ample protein efficiently—restriction offers no benefit and risks muscle loss (sarcopenia). Cancer patients often need 1.2-1.5 g/kg protein daily to combat cachexia, per guidelines. Cirrhosis protocols emphasize adequate (1.0-1.5 g/kg) or higher intake, especially with hepatic encephalopathy history.

"Reducing the protein consumption may be the easiest way to get ammonia levels down," Zong advises, but only under medical supervision. Self-prescribing ignores variables like frailty, dialysis, or treatment phase. Risks include malnutrition, weakened immunity, and slowed healing.

• Avoid if no liver impairment.
• Monitor for fatigue, edema.
• Pair with veggies, carbs for balance.

Actionable Advice for Liver-Healthy Eating

Consult a hepatologist or dietitian for tailored plans. General tips for moderate reduction:

• Prioritize quality: Lean fish, legumes over red meat.
• Aim 0.8-1.2 g/kg if advised, tracking via apps.
• Boost veggies/fruits for fiber, antioxidants.
• Hydrate to aid urea excretion.
• Supplement if deficient (e.g., branched-chain amino acids).

Sample day: Oatmeal breakfast, lentil soup lunch, quinoa-salmon dinner—totaling ~60-80g protein for 70kg person.

Photo by Nature Zen on Unsplash

Looking Ahead: From Mice to Human Trials

While preclinical, parallels exist: Human HCC shows UCE downregulation. No dedicated trials yet, but protein modulation in cirrhosis (e.g., for encephalopathy) provides precedent. Future: Phase II studies in high-risk cohorts, ammonia-targeted drugs, or combo with immunotherapy.

Related work, like tryptophan restriction slowing HCC or low-carb/high-protein paradoxically aiding some tumors, underscores nuance. Rutgers' innovation inspires broader metabolic oncology research.

Connecting Research to Careers in Academia

Discoveries like this Rutgers study highlight the vital role of biomedical research in health breakthroughs. Aspiring scientists can explore research jobs or clinical research jobs in higher education to contribute to cancer metabolism studies. Platforms like Rate My Professor let you learn from experts like Wei-Xing Zong.

For career advice, check how to write a winning academic CV. Job seekers, browse higher ed jobs including faculty positions at institutions driving such innovations. Share your insights in the comments below and have your say on pivotal research.